Novel antibacterial ozenoxacin (Ferrer) enters Phase III for treatment for Impetigo

Ferrer has received approval to initiate Phase III clinical trials of ozenoxacin as a topical treatment for infectious dermatological conditions such as Impetigo. Ozenoxacin is a novel second generation non-fluorinated quinolone antibacterial agent. The first patients are expected to enter the trials in February 2012 and the studies are scheduled to complete in the first quarter, 2013. The multicentre clinical study comparing ozenoxacin one per cent cream versus placebo will be conducted in about 465 patients up to two years old with a clinical diagnosis of non-bullous or bullous Impetigo at approximately 50 centres in the USA, South Africa, Germany, Romania, India and the Ukraine, subject to completion of additional regulatory approvals. In addition to development in Impetigo and other dermatological conditions, ozenoxacin is being assessed for its potential to be developed in a variety of systemic indications, such as bone and joint infections and pulmonary infections.